Equities Analysts Offer Predictions for AXSM Q1 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – HC Wainwright cut their Q1 2025 EPS estimates for shares of Axsome Therapeutics in a report released on Thursday, February 20th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($1.06) for the quarter, down from their previous forecast of ($0.85). HC Wainwright has a “Buy” rating and a $200.00 price target on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at ($1.93) EPS, Q2 2026 earnings at $1.16 EPS, Q3 2026 earnings at $2.43 EPS and Q4 2026 earnings at $3.82 EPS.

A number of other analysts have also weighed in on the company. Royal Bank of Canada raised their target price on Axsome Therapeutics from $143.00 to $192.00 and gave the company an “outperform” rating in a research note on Wednesday, February 19th. Robert W. Baird set a $132.00 price objective on shares of Axsome Therapeutics in a research report on Monday, February 3rd. StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Needham & Company LLC increased their price target on shares of Axsome Therapeutics from $133.00 to $153.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Finally, Truist Financial boosted their price objective on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $158.79.

Axsome Therapeutics Trading Down 5.1 %

Shares of AXSM opened at $130.72 on Monday. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.37 and a current ratio of 2.11. The company has a market cap of $6.37 billion, a price-to-earnings ratio of -21.82 and a beta of 1.05. The stock has a fifty day moving average price of $102.11 and a two-hundred day moving average price of $95.31. Axsome Therapeutics has a 52-week low of $64.11 and a 52-week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. The company had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

Insider Transactions at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 22.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Axsome Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Raiffeisen Bank International AG acquired a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $51,000. Assetmark Inc. bought a new stake in Axsome Therapeutics in the fourth quarter valued at approximately $52,000. R Squared Ltd acquired a new stake in Axsome Therapeutics in the fourth quarter worth $64,000. Aquatic Capital Management LLC bought a new position in shares of Axsome Therapeutics during the fourth quarter worth $76,000. Finally, GF Fund Management CO. LTD. bought a new position in shares of Axsome Therapeutics during the fourth quarter worth $86,000. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.